Johnson & Johnson will discontinue the Phase II Auτonomy study of posdinemab after a scheduled review found the anti-tau ...
Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease drug has been rocked by a phase 2 flop. | Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease ...
J&J is also running mid-stage trials of a tau active immunotherapy codenamed JNJ-2056 for Alzheimer's, while other active tau ...
There’s only one way to attack a worn trope, and that’s to bring it. Federico D’Alessandro, a veteran storyboard artist for Marvel, doesn’t in his debut feature. Julia, of course, finds out she’s ...
A computer scientist imprisons human subjects to train the ultimate artificial intelligence in Federico D'Alessandro's sci-fi captivity film 'TAU.' By THR Staff A stylish B-movie flipping the script ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results